CN104045615B - (1s)-1-[4-氯-3-(4-乙氧基苄基)苯基]-1,6-二脱氧-d-葡萄糖的晶型a及其制备方法和应用 - Google Patents

(1s)-1-[4-氯-3-(4-乙氧基苄基)苯基]-1,6-二脱氧-d-葡萄糖的晶型a及其制备方法和应用 Download PDF

Info

Publication number
CN104045615B
CN104045615B CN201310239524.1A CN201310239524A CN104045615B CN 104045615 B CN104045615 B CN 104045615B CN 201310239524 A CN201310239524 A CN 201310239524A CN 104045615 B CN104045615 B CN 104045615B
Authority
CN
China
Prior art keywords
crystal form
glucose
dideoxy
phenyl
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201310239524.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN104045615A (zh
Inventor
赵桂龙
刘冰妮
魏群超
王玉丽
刘鹏
李川
张海枝
徐为人
汤立达
邹美香
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guangzhou Lixin Pharmaceuticals Co ltd
Tianjin Institute of Pharmaceutical Research Co Ltd
Original Assignee
Tianjin Institute of Pharmaceutical Research Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tianjin Institute of Pharmaceutical Research Co Ltd filed Critical Tianjin Institute of Pharmaceutical Research Co Ltd
Priority to CN201310239524.1A priority Critical patent/CN104045615B/zh
Priority to PCT/CN2014/073365 priority patent/WO2014139447A1/fr
Publication of CN104045615A publication Critical patent/CN104045615A/zh
Application granted granted Critical
Publication of CN104045615B publication Critical patent/CN104045615B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN201310239524.1A 2013-03-15 2013-06-17 (1s)-1-[4-氯-3-(4-乙氧基苄基)苯基]-1,6-二脱氧-d-葡萄糖的晶型a及其制备方法和应用 Active CN104045615B (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN201310239524.1A CN104045615B (zh) 2013-03-15 2013-06-17 (1s)-1-[4-氯-3-(4-乙氧基苄基)苯基]-1,6-二脱氧-d-葡萄糖的晶型a及其制备方法和应用
PCT/CN2014/073365 WO2014139447A1 (fr) 2013-03-15 2014-03-13 Forme cristalline a de (1s)-1-[4-chloro-3-(4-éthoxybenzyl)phényl]-1,6-didésoxy-d-glucose et procédé de préparation et utilisation de celle-ci

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201310084842 2013-03-15
CN201310084842.5 2013-03-15
CN201310239524.1A CN104045615B (zh) 2013-03-15 2013-06-17 (1s)-1-[4-氯-3-(4-乙氧基苄基)苯基]-1,6-二脱氧-d-葡萄糖的晶型a及其制备方法和应用

Publications (2)

Publication Number Publication Date
CN104045615A CN104045615A (zh) 2014-09-17
CN104045615B true CN104045615B (zh) 2015-11-18

Family

ID=51499059

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201310239524.1A Active CN104045615B (zh) 2013-03-15 2013-06-17 (1s)-1-[4-氯-3-(4-乙氧基苄基)苯基]-1,6-二脱氧-d-葡萄糖的晶型a及其制备方法和应用

Country Status (2)

Country Link
CN (1) CN104045615B (fr)
WO (1) WO2014139447A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016155578A1 (fr) * 2015-03-27 2016-10-06 苏州晶云药物科技有限公司 Nouvelle forme cristalline de dapagliflozine et son procédé de préparation
CN108675976B (zh) * 2018-05-14 2020-07-14 浙江宏元药业股份有限公司 一种6-卤代葡萄糖碳苷及其制备方法和应用
CN111559997A (zh) * 2019-02-13 2020-08-21 罗欣药业(上海)有限公司 一种达格列净新晶型及其制备方法
EP4114365A1 (fr) 2020-03-05 2023-01-11 KRKA, d.d., Novo mesto Composition pharmaceutique comprenant un inhibiteur du sglt2

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101065391A (zh) * 2004-09-23 2007-10-31 布里斯托尔-迈尔斯斯奎布公司 C－芳基葡糖苷sglt2抑制剂和方法
CN102408459A (zh) * 2011-09-29 2012-04-11 天津药物研究院 一类含异头位烷基的苯基c-葡萄糖苷衍生物、其制备方法和用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101065391A (zh) * 2004-09-23 2007-10-31 布里斯托尔-迈尔斯斯奎布公司 C－芳基葡糖苷sglt2抑制剂和方法
CN102408459A (zh) * 2011-09-29 2012-04-11 天津药物研究院 一类含异头位烷基的苯基c-葡萄糖苷衍生物、其制备方法和用途

Also Published As

Publication number Publication date
WO2014139447A1 (fr) 2014-09-18
CN104045615A (zh) 2014-09-17

Similar Documents

Publication Publication Date Title
EP2870163B1 (fr) Compositions pharmaceutiques comprenant de la rifaximine et des acides aminés, procédé de préparation et utilisation correspondants
CN104045615B (zh) (1s)-1-[4-氯-3-(4-乙氧基苄基)苯基]-1,6-二脱氧-d-葡萄糖的晶型a及其制备方法和应用
CN104098586A (zh) 含腈基的噻吩并吡啶脂类衍生物的晶型、其制法和应用
CN101671337B (zh) 枸橼酸爱地那非晶型a及其制备方法和用途
CN101095670A (zh) 木犀草素磷脂复合物及其制备方法和应用
CN101597272B (zh) 艾拉莫德的钾盐化合物,其制备方法和药物应用
CN101691372A (zh) 枸橼酸爱地那非晶型c及其制备方法和用途
CN105001195A (zh) R(+)-硫辛酸-l-赖氨酸盐的新晶型及其制备方法
CN104045614B (zh) (1s)-1-[4-氯-3-(4-乙氧基苄基)苯基]-1,6-二脱氧-d-葡萄糖的晶型c及其制备方法和应用
CN104045613B (zh) (1s)-1-[4-氯-3-(4-乙氧基苄基)苯基]-1,6-二脱氧-d-葡萄糖和l-脯氨酸的共结晶i及其制备方法和应用
CN104693192A (zh) 一种化合物的晶型a及其制备方法和应用
CN104910147B (zh) 阿哌沙班晶体及其制备方法
CN104610208B (zh) (1s)‑1,6‑二脱氧‑1‑[4‑甲氧基‑3‑(反式‑4‑正丙基环己基)甲基苯基]‑d‑吡喃葡萄糖的晶型a及其制备方法和应用
US20080255231A1 (en) Polymorphs of rivastigmine hydrogentartrate
CN106279017A (zh) 贝达喹啉晶型、组合物及其制备方法
CN104693190A (zh) 一种化合物的晶型b及其制备方法和应用
CN104693191A (zh) 一种共结晶i及其制备方法和应用
CN103819446B (zh) 1,3,6,7-四甲氧基山酮的晶型及其药物组合物、制备方法与应用
CN107074744B (zh) Nep抑制剂结晶型游离酸、钙盐多晶型及其制备方法和应用
WO2008125134A1 (fr) Procédé de préparation d'adsorbats de périndopril-tert-butylamine
CN101735040B (zh) 索法酮的晶型ⅲ及其制备方法和用途
CN101781193B (zh) 索法酮的晶型ⅳ及其制备方法和用途
CN105315230A (zh) 无定型形态的匹维溴铵
CN101781192B (zh) 索法酮的晶型ⅵ及其制备方法和用途
CN101781194B (zh) 索法酮的晶型ⅴ及其制备方法和用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CP01 Change in the name or title of a patent holder

Address after: 300193 Tianjin City, Nankai District Anshan West Road No. 308

Patentee after: Tianjin Institute of Pharmaceutical Research Co.,Ltd.

Address before: 300193 Tianjin City, Nankai District Anshan West Road No. 308

Patentee before: Tianjin Institute of Pharmaceutical Research

CP03 Change of name, title or address
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20170406

Address after: Guangzhou hi tech Development Zone 510663 Guangdong Science City skim Springs Road No. 3, Guangzhou international business incubator A A1206

Patentee after: GUANGZHOU LIXIN PHARMACEUTICALS CO.,LTD.

Address before: 300193 Tianjin City, Nankai District Anshan West Road No. 308

Patentee before: Tianjin Institute of Pharmaceutical Research Co.,Ltd.